MitoRx Therapeutics
5 known investors
MitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.
Founders & leadership
JR
Jon R.inFounder · Chief Executive OfficerJon Rees is the founder and CEO of MitoRx Therapeutics, a preclinical biotech developing mitochondrial-targeted small molecules for weight loss in obesity. A metabolic engineer, he holds a PhD in engineering plant secondary metabolism from Royal Holloway University of London, completed postdoctoral work on primary metabolism at the University of Oxford, and previously helped secure the first venture investment in Ducentis, which was later acquired.
Investors · 5
Funding
SEC filings, press & company announcements- Undisclosed amountpre-series A roundNov 2025Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does MitoRx Therapeutics do?
- MitoRx is a preclinical-stage biotech developing MTRX31, a first-in-class small molecule that restores mitochondrial metabolism to eliminate ectopic fat in patients with metabolically unhealthy, high-risk obesity. Rather than suppressing appetite, its approach aims to deliver durable weight loss and reduce risks of type 2 diabetes, MASH, and cardiovascular disease.
- Who founded MitoRx Therapeutics?
- MitoRx Therapeutics was founded by Jon R..
- Who are MitoRx Therapeutics's investors?
- MitoRx Therapeutics's investors include Future Planet Capital, Oxford Investment Opportunity Network (OION), Oxford Technology Management, UK Innovation & Science Seed Fund, Wren Capital.